IFN-alpha: therapeutic options in HIV and HIV/HCV, HIV/HBV dual infection.
The antiviral effects of interferon-alpha (IFN-alpha) are well documented for the treatment of hepatitis B or C infections, whereas antiretroviral effects for treatment of HIV-1 infection have been investigated up to now only in small-sized preclinical studies. New preclinical and clinical data on IFN-alpha for HIV, HCV, HBV and especially on co-infections of HIV with HCV or HBV were presented at a symposium of the ConVir conference 2002. This short paper summarizes the presented data on IFN-alpha treatment for HIV and/or HCV or HBV infections.
Jablonowski
H
H
Klinikum Salzgitter, Kattowitzer Strasse 191, D-3822 Salzgitter, Germany. h.jablonowski@klinikum-salzgitter.de
D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D000998:Antiviral Agents / Q000627:therapeutic use*; D006678:HIV / Q000302:isolation & purification / Q000378:metabolism; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy* / Q000635:transmission; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D019562:Viral Load / Q000379:methods
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D016898:Interferon-alpha